Grail's multi-cancer test fluffs its lines in UK trial
Grail's Galleri blood test for cancer screening missed the mark in the much-anticipated NHS-Galleri trial, wreaking havoc with the firm's share price.
Newsletters and Deep Dive digital magazine
Grail's Galleri blood test for cancer screening missed the mark in the much-anticipated NHS-Galleri trial, wreaking havoc with the firm's share price.
Daiichi Sankyo has named John Tsai as its new chief medical officer, replacing Ken Takeshita, who is stepping down after five years in the role.
MSD has signed an industry-first deal with the Mayo Clinic that will allow it to use the health system's genomic and clinical data for drug discovery.
A report has found that the number of life sciences companies domiciled in the UK has grown by nearly a quarter in the last few years.
Novartis is set to expand the label for its oral BTK inhibitor Rhapsido, keeping the drug on course to become one of its biggest-ever brands.
Editor's Picks
Newsletters and Deep Dive
digital magazine